

Monday, September 13th, 2021

12:00am (CET) / Login: <https://www.sunrise-network.fr/event/sunrise-webinar-mark-dawson-melbourne/>

Cancer Epigenetics: Concepts, Challenges and Therapeutic Opportunities



Pr Mark Dawson, MD, PhD

Peter MacCallum Cancer Centre and Centre for Cancer Research
University of Melbourne (Australia)

Biography

Mark Dawson is a clinician-scientist at the Peter MacCallum Cancer Centre and Centre for Cancer Research University of Melbourne (Australia). His work focuses on understanding the role that epigenetic regulators play in the initiation and maintenance of cancer. Moreover, he uncovers several epigenetic mechanisms by which malignancies evade therapeutic pressure. He pioneered the development of BET inhibitor and the use of click chemistry in vivo.

Selected publications

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immune-inflammation". Gilan et al., **Science** 2020

HBO1 is required for the maintenance of leukaemia stem cells. MacPherson et al., **Nature** 2020

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Bell et al., **Nature Comm** 2019

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Burr et al., **Nature** 2017

Click chemistry enables preclinical evaluation of targeted epigenetic therapies". Tyler et al., **Science**, 2017